RxDoctor Payments Data

Casandra Mateo, MD

Neurology · Atlantis, FLNPI 1477567691

Payments from drug & device makers

$10,582in general payments, 2019–2025

Across 510 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • MDD US Operations, LLC$725
  • Pfizer$536
  • Neurocrine Biosciences, Inc.$454
  • Biohaven Pharmaceuticals, Inc.$390
  • plus $4K from 42 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$10,532100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,582 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$166,661
Medicare patients
547
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam44$75,299
Nurtec OdtRimegepant Sulfate50$51,758
UbrelvyUbrogepant44$49,860
Aimovig AutoinjectorErenumab-Aooe48$43,048
QuliptaAtogepant36$40,711
Glatiramer Acetate15$40,320
NayzilamMidazolam22$39,795
RexultiBrexpiprazole20$37,127
Lacosamide126$29,964
XcopriCenobamate13$23,112
FycompaPerampanel11$18,108
AptiomEslicarbazepine Acetate12$15,007
Levetiracetam475$13,466
Memantine Hcl281$10,176
LamictalLamotrigine12$7,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$1,689$115,09566 claims
AbbVieUbrelvy, Qulipta$2,328$90,57080 claims
PfizerNurtec Odt$536$51,75850 claims
Otsuka America Pharmaceutical, Inc.Rexulti$153$37,12720 claims
SK Life Science, Inc.Xcopri$385$23,11213 claims
Eisai Inc.Fycompa$294$18,10811 claims
Sunovion Pharmaceuticals Inc.Aptiom$19$15,00712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →